Spots Global Cancer Trial Database for peptide vaccine
Every month we try and update this database with for peptide vaccine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Melanoma Vaccine With Peptides and Leuprolide | NCT00254397 | Melanoma | Leuprolide GP100: 209-217(... MAGE-3 Peptide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | NCT02126579 | Melanoma Metastatic Mela... Mucosal Melanom... | Peptide Vaccine... PolyICLC Resiquimod IFA | 18 Years - | University of Virginia | |
| Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC | NCT05950139 | NSCLC Stage IV ALK Fusion Prot... | Peptide vaccine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC | NCT05950139 | NSCLC Stage IV ALK Fusion Prot... | Peptide vaccine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | NCT04270149 | Breast Cancer | ESR1 peptide va... | 18 Years - | Duke University | |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer | NCT00681330 | Esophageal Canc... | URC10, TTK, KOC... | 20 Years - 85 Years | Tokyo University | |
| Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer | NCT04024800 | Triple-negative... | AE37 Peptide va... Pembrolizumab | 18 Years - | NuGenerex Immuno-Oncology | |
| First-in-human Study of S-588210 (S-488210+S-488211) | NCT04316689 | Lung Cancer Head and Neck C... Bladder Cancer Esophageal Canc... Mesothelioma | S-488210 S-488211 | 18 Years - | Shionogi Inc. | |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients | NCT01585350 | Melanoma | MELITAC 12.1 + ... MELITAC 12.1 + ... | 18 Years - | University of Virginia | |
| Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides | NCT02429440 | Renal Cell Canc... Advanced Renal ... | peptide vaccine Granulocyte Mac... Montanide ISA-5... | 18 Years - | University Hospital Tuebingen | |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | NCT02452307 | Recurrent Prost... | Peptide vaccine Montanide ISA-5... Granulocyte mac... Imiquimod mRNA Protamin local hyperther... | 45 Years - 80 Years | University Hospital Tuebingen | |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer | NCT00681577 | Gastric Cancer | URLC10, KOC1, V... | 20 Years - 85 Years | Tokyo University | |
| A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | NCT02754362 | Glioblastoma Glioma | Bevacizumab Peptide Vaccine Poly-ICLC as im... Keyhole limpet ... | 18 Years - | NYU Langone Health | |
| PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment | NCT00694551 | Prostate Cancer | Peptide Vaccine Poly IC-LC | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer | NCT00753844 | Esophageal Canc... | URLC10 | 20 Years - 80 Years | Kinki University | |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | NCT05609994 | Low Grade Gliom... | PEPIDH1M vaccin... | 18 Years - | Duke University | |
| Vaccination With PD-L1 Peptide Against Multiple Myeloma | NCT03042793 | Multiple Myelom... | PD-L1 peptide v... | 18 Years - | Herlev Hospital | |
| Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | NCT00267085 | Chronic Myeloid... Minimal Residua... | Synthetic Tumor... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | NCT05243862 | Colorectal Canc... | PolyPEPI1018 Atezolizumab | 18 Years - | Treos Bio Limited | |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer | NCT00677326 | Breast Cancer | VEGFR1 and VEGF... | 20 Years - 85 Years | Tokyo University | |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer | NCT00681252 | Gastric Cancer | URLC10, VEGFR1 ... | 20 Years - 85 Years | Tokyo University | |
| A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. | NCT01789099 | Non-small Cell ... | UV1 synthetic p... | 18 Years - | Ultimovacs ASA | |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients | NCT01585350 | Melanoma | MELITAC 12.1 + ... MELITAC 12.1 + ... | 18 Years - | University of Virginia | |
| Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma | NCT01266707 | Hepatocellular ... | antiangiogenic ... | 20 Years - 80 Years | Fukushima Medical University | |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer | NCT00753844 | Esophageal Canc... | URLC10 | 20 Years - 80 Years | Kinki University | |
| Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma | NCT01264731 | Melanoma | MELITAC 12.1 Imiquimod | 18 Years - | University of Virginia | |
| Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma | NCT00977145 | Melanoma | A combination o... | 18 Years - | University of Virginia | |
| Vaccination With PD-L1 Peptide Against Multiple Myeloma | NCT03042793 | Multiple Myelom... | PD-L1 peptide v... | 18 Years - | Herlev Hospital | |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | NCT05609994 | Low Grade Gliom... | PEPIDH1M vaccin... | 18 Years - | Duke University | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | NCT03662815 | Advanced Malign... | iNeo-Vac-P01 GM-CSF | 18 Years - 75 Years | Sir Run Run Shaw Hospital | |
| Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides | NCT02429440 | Renal Cell Canc... Advanced Renal ... | peptide vaccine Granulocyte Mac... Montanide ISA-5... | 18 Years - | University Hospital Tuebingen | |
| A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. | NCT01789099 | Non-small Cell ... | UV1 synthetic p... | 18 Years - | Ultimovacs ASA | |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer | NCT00673777 | Non Small Cell ... | URLC10, VEGFR1 ... | 20 Years - 85 Years | Tokyo University | |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer | NCT00674258 | Non Small Cell ... | URLC10, TTK and... | 20 Years - 85 Years | Tokyo University | |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer | NCT00681577 | Gastric Cancer | URLC10, KOC1, V... | 20 Years - 85 Years | Tokyo University | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco | |
| HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1) | NCT01266720 | Pancreatic Canc... | VEGFR1, VEGFR2 Gemcitabine | 20 Years - 80 Years | Fukushima Medical University | |
| Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant | NCT02947854 | Healthy Volunte... | Fimaporfin (Pho... Hiltonol (Poly-... HPV E7 (Human P... KLH (Keyhole Li... | 18 Years - 55 Years | PCI Biotech AS | |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer | NCT00845611 | Gastric Cancer | peptide vaccine | 20 Years - 80 Years | Kinki University | |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer | NCT00678509 | Breast Cancer | TTK peptide mix... | 20 Years - 85 Years | Tokyo University | |
| Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC | NCT05950139 | NSCLC Stage IV ALK Fusion Prot... | Peptide vaccine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | NCT04270149 | Breast Cancer | ESR1 peptide va... | 18 Years - | Duke University | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) | NCT00415857 | Leukemia | Peptide Vaccine... Peginterferon a... Imatinib GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| First-in-human Study of S-588210 (S-488210+S-488211) | NCT04316689 | Lung Cancer Head and Neck C... Bladder Cancer Esophageal Canc... Mesothelioma | S-488210 S-488211 | 18 Years - | Shionogi Inc. | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
